Opinion
Video
Author(s):
Panelists discuss how health care providers can effectively communicate the benefits and risks of JAK inhibitors to patients with atopic dermatitis while addressing safety concerns and establishing realistic treatment expectations.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.